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Abstract: Maintaining optimal low-density lipoprotein (LDL) cholesterol levels is necessary to
prevent cardiovascular disease (CVD). Excessive fat mass and decreased muscle mass are both
associated with increased risks of developing dyslipidemia. Thus, we investigated the longitudinal
relationship between the fat-to-muscle ratio (FMR) and the non-achievement of LDL cholesterol
targets. We analyzed a total of 4386 participants aged 40–69 years from the Korean Genome and
Epidemiology Study. FMR was defined as the ratio of total fat mass to total muscle mass, measured
by bioelectrical impedance. The non-achievement of an LDL cholesterol target was defined as an
LDL cholesterol level higher than the established target level according to individual CVD risk. The
adjusted hazard ratios and 95% confidence interval for the incidence of non-achievement of LDL
cholesterol targets for the sex-specific middle and highest tertiles vs. the referent lowest tertile of FMR
were 1.56 (1.29–1.90) and 1.86 (1.47–2.31) in men and 1.40 (1.18–1.66) and 1.31 (1.06–1.62) in women
after adjusting confounders. Our findings suggest that FMR, a novel indicator of the combined effects
of fat and muscle mass, is useful for predicting non-achievement of LDL cholesterol targets.
Keywords: fat-to-muscle ratio; fat mass; muscle mass; low-density lipoprotein cholesterol;
cardiovascular risk; cohort study
1. Introduction
Obesity is a major public health problem worldwide due to its high prevalence and
heavy burden on individuals and societies. Numerous pieces of clinical and epidemiologi-
cal evidence have demonstrated the strong link between obesity and cardiovascular disease
(CVD) development [1], and excessive adipose tissue has been shown to worsen CVD risk
factors, such as insulin resistance, abnormal glucose and lipid metabolism, hypertension,
and inflammation [2,3].
The most significant contributing factor in obesity-related dyslipidemia has been
identified as elevated free fatty acid (FFA) levels due to increased FFA release from adipose
tissue and a reduction in plasma FFA clearance [4]. Increased FFA levels result in increased
levels of triglycerides, decreased levels of high-density lipoprotein (HDL) cholesterol, and
the increased presence of small, dense, low-density lipoprotein (LDL) particles, which
are associated with increased risk of CVD [4,5]. Excess body fat accumulation, even in
non-obese people, has been reported to be related to dyslipidemia [6]. In addition, Lee et al.
demonstrated that decreased skeletal muscle mass was also associated with dyslipidemia,
regardless of the presence of abdominal obesity, and suggested that insulin resistance may
be associated with low muscle mass [7]. Thus, both excessive fat mass and the relative
decrease in muscle mass should be considered when examining the associations between
obesity and dyslipidemia.
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Body mass index (BMI) is the most widely used indicator of obesity and can be
measured with relative ease by both clinicians and patients. However, BMI cannot be used
as a direct measure of body composition, which represents a major limitation because the
same BMI can represent a variety of body compositions associated with differing health
outcomes [8,9]. This limitation of BMI has led to the suggested use of other anthropometric
indicators to evaluate central obesity or adiposity, such as waist circumference, waist–hip
ratio, or body fat percentage [10,11]. Recently, the fat-to-muscle ratio (FMR) has been
proposed as a novel indicator to assess the combined effects of fat and skeletal muscle mass.
Several studies have reported that the FMR is associated with metabolic syndrome [12,13],
insulin resistance [14], and nonalcoholic fatty liver disease [15]. However, the relationship
between FMR and the risk of dyslipidemia is not yet known.
Maintaining an optimal LDL cholesterol level is emphasized to prevent CVD, and
many international working groups have recommended the use of individualized target
LDL cholesterol levels for the management of CVD based on individual CVD risk lev-
els [16,17]. Therefore, this study aimed to investigate whether high FMR is associated with
the non-achievement of LDL cholesterol targets among adults with optimal LDL choles-
terol levels at baseline, using a large-sample, community-based Korean cohort observed
over 12 years. Furthermore, we compared the predictive power of FMR and BMI for the
non-achievement of LDL cholesterol targets.
2. Materials and Methods
2.1. Study Population
All data used in this study derived from the Korean Genome and Epidemiology Study
(KoGES)-Ansan and Ansung study. The KoGES_Ansan and Ansung study is a longitudinal,
prospective, cohort study initiated by the Korean National Institute of Health to evaluate
risk factors for non-communicable diseases [18]. The survey was conducted biennially
from 2001 to 2002 (baseline survey) and 2013 to 2014 (sixth follow-up). Figure 1 displays
a flowchart of the study population selection process. From a total of 10,030 community-
dwelling individuals aged 40–69 years who participated in the baseline survey, we excluded
(1) individuals missing body composition data measured by bioelectrical impedance analy-
sis (BIA; n = 2191); (2) participants with serum triglyceride level ≥ 400 mg/dL (n = 222);
(3) participants who did not achieve the LDL cholesterol target at baseline (n = 2140); and
(4) those who were not followed up after the baseline survey (n = 1254). Data from a total
of 4223 participants (including 1858 men and 2365 women) were analyzed in this study.J. Cardiovasc. Dev. Dis. 2021, 8, x FOR PEER REVIEW 3 of 15  
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2.2. Assessment of the LDL Cholesterol Target Levels Based on CVD Risk Levels
At each follow up time, participants were categorized into 4 groups based on their
CVD risk levels: low-risk group, moderate-risk group, high-risk group, and very high
risk group. Participants who presented with 0 or 1 major CVD risk factors were classified
into the low-risk group. The moderate-risk group comprised participants with ≥2 major
CVD risk factors. Participants with diabetes mellitus but without signs of target organ
damage (glomerular filtration rate < 60 mL/min/1.73 m2, albuminuria, or the concurrence
of hypertension) were categorized into the high-risk group. Participants with a prior
history of coronary artery disease, ischemic stroke, or transient ischemic attack and diabetic
patients with signs of target organ damage and reported current smoking at baseline
were classified into the very high risk group. The major risk factors for CVD included
(1) men aged ≥ 45 years and women aged ≥ 55 years; (2) systolic blood pressure (SBP)
≥ 140 mmHg, diastolic blood pressure (DBP) ≥ 90 mmHg, or current treatment with
antihypertensive medications ≥ 20 days/month; (3) current smoking; (4) serum HDL
cholesterol levels < 40 mg/dL; and (5) family history (parents or siblings) of premature
CVD that developed < 55 years in men and < 65 years in women. Serum HDL cholesterol
levels ≥ 60 mg/dL were considered to be a protective factor against CVD risk [19].
The LDL cholesterol target levels were set according to CVD risk levels as follows:
<160 mg/dL for the low-risk group, <130 mg/dL for the moderate-risk group, <100 mg/dL
for the high-risk group, and <70 mg/dL for the very high risk group [19]. We defined the
non-achievement of an LDL cholesterol target when the LDL cholesterol level was higher
than the defined LDL cholesterol target for the established CVD risk level. Participants’
CVD risk levels were assessed at each follow-up period as well as non-achievement of LDL
cholesterol targets according to their CVD risk levels.
2.3. Assessment of Body Composition
Each participant’s body composition was analyzed using a multi-frequency BIA
machine (Inbody 330; Biospace, Seoul, Korea) featuring eight tactile electrode points,
which has been validated in previous studies as a reliable tool for the assessment of body
composition [20–22]. Height (m) and weight (kg) were measured to the nearest 0.1 cm
and 0.1 kg, respectively. BMI was calculated as the weight divided by height squared
(kg/m2). A BMI greater than 25 kg/m2 was considered obese according to the definitions
established by the Korean Society for the Study of Obesity [23]. Waist circumference (cm)
was measured in the horizontal plane, midway between the iliac crest and the lowest rib.
In addition, total fat mass (kg) and total skeletal muscle mass (kg) were evaluated. FMR
was defined as the ratio between total fat mass and total skeletal muscle mass. Participants
were classified into 3 groups according to sex-specific FMR tertiles: T1, FMR < 0.241; T2,
FMR of 0.241–0.314; and T3 FMR > 0.314 in men; T1, FMR < 0.439; T2 FMR of 0.439–0.527;
and T3 FMR > 0.527 in women.
2.4. Data Collection
After at least 30 min of rest, SBP and DBP were measured in a seated position. Mean
blood pressure (MBP; mmHg) was calculated using the following equation: MBP = (SBP
+ 2 × DBP)/3. Alcohol intake status was classified according to whether the participant
was a current drinker. Smoking status was classified according to whether the participant
was a current smoker. Physical activity was assessed using metabolic equivalent of task
(MET)-hours per week (METs-hr/wk). MET was obtained from the participant’s report
on hours spent on sleep and 5 types of physical activities according to intensity including
heavy, moderate, light, very light, and sedentary, corresponding 7 MET, 5 MET, 3 MET,
1.5 MET, and 0 MET, respectively. Total METs-hr/wk were calculated by multiplying
the reported hours spent per week by the MET values that were calculated based on
each type of activity. The degree of physical activity was classified into 3 categories:
<7.5 MET-hr/wk, 7.5–30 MET-hr/wk, and >30 MET-hr/wk. A blood sample from each
participant was collected from the antecubital vein after at least 8 h of fasting. Plasma
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glucose, serum insulin, total cholesterol, triglyceride, HDL cholesterol, and C-reactive
protein (CRP) levels were measured using a Hitachi 7600 Analyzer (Hitachi Co., Tokyo,
Japan). For participants with serum triglyceride level < 400 mg/dL, LDL cholesterol levels
were calculated using the Friedewald equation: LDL cholesterol (mg/dL) = total cholesterol
– HDL cholesterol – triglycerides/5 [24]. For the assessment of each participant’s diet, a
24 h dietary recall method was used. Total calorie intake (kcal/day), carbohydrate intake
(g/day), fat intake (g/day), and protein intake (g/day) were calculated. Hypertension
was defined using the following criteria: (1) SBP ≥ 140 mmHg, (2) DBP ≥ 90 mmHg, or
(3) treatment with antihypertensive medications [25]. Diabetes mellitus was defined using
the following criteria: (1) fasting plasma glucose level ≥ 126 mg/dL; (2) 2 h plasma glucose
level ≥ 200 mg/dL after a 75 g oral glucose tolerance test; (3) glycosylated hemoglobin
(HbA1c) ≥ 6.5%; or (4) treatment with antidiabetic medications [26]. Participants’ status of
taking anti-dyslipidemic medication was obtained from a self-reported questionnaire given
to each participant. Anti-dyslipidemic medication status was categorized into two groups.
2.5. Statistical Analysis
All data analyzed in this study are presented as the mean ± standard deviation or
the median (25th percentiles, 75th percentiles) for continuous variables and as the number
(percent, %) for categorical variables. To compare differences in continuous variables
among the defined sex-specific FMR tertile groups, analysis of variance (ANOVA) or the
Kruskal–Wallis test was used. Chi-square tests were used to compare categorical variables.
A Cox proportional hazard spline curve was used to verify the linearity of the relationship
between FMR and the incidence of non-achievement of LDL cholesterol targets. Kaplan–
Meier curves were used to assess the cumulative incidence of non-achievement of LDL
cholesterol targets according to the sex-specific FMR tertiles. The log-rank test was used
to assess among-group comparisons of the distribution of the cumulative incidence of
non-achievement of LDL cholesterol targets. Cox proportional hazard regression analysis
was used to calculate the hazard ratio (HR) with a 95% confidence interval (CI) for incident
non-achievement of LDL cholesterol targets in the T2 and T3 tertiles vs. the referent T1
tertile according to sex. Generalized estimating equation (GEE) models were generated
to determine the relationship between baseline FMR and the longitudinal proportion of
non-achievement of LDL cholesterol targets according to the sex-specific FMR tertiles.
Receiver operating characteristic (ROC) curves were used to compare the discriminative
power of FMR and BMI to predict the non-achievement of LDL cholesterol targets using
the area under the ROC curve (AUC). All statistical analyses were conducted using SPSS
statistical software (version 25.0; SPSS Inc., Chicago, IL, USA), SAS statistical software
(version 9.4; SAS Institute Inc., Cary, NC, USA), and R (Version 4.0.3; R Foundation for
Statistical Computing, Vienna, Austria). p < 0.05 was considered statistically significant.
3. Results
3.1. Clinical Characteristics of the Study Population
The baseline characteristics of the study population are represented in Table 1. For
both men and women, mean age, BMI, MBP, plasma glucose, serum total cholesterol,
LDL cholesterol levels, median serum triglyceride levels, and the proportion of obese
participants and people with hypertension were significantly increased in the sex-specific
T3 tertile compared with the T1 tertile. The mean value of serum HDL cholesterol levels
and the proportion of participants who exercised > 30 METs-h/week were significantly
decreased in the sex-specific T3 tertile compared with the T1 tertile for both men and
women. In men but not women, the proportion of current smokers significantly decreased
in the T3 tertile compared with the T1 tertile. In women but not men, the proportion of
current drinkers significantly decreased in the T3 tertile compared with the T1 tertile.
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Table 1. Baseline characteristics of the study population.
Men Women
Fat-to-Muscle Ratio T1 (<0.241) T2 (0.241–0.314) T3 (>0.314) p T1 (<0.439) T2 (0.439–0.527) T3 (>0.527) p
Number, n 620 619 619 789 787 789
Age, years 50.6 ± 8.8 50.3 ± 8.5 51.4 ± 8.6 0.096 49.0 ± 8.4 49.7 ± 8.2 51.7 ± 8.7 <0.001
BMI, kg/m2 21.6 ± 2.2 23.9 ± 2.0 26.3 ± 2.3 <0.001 21.9 ± 2.0 24.3 ± 1.9 27.3 ± 2.7 <0.001
Obese, n (%) 35 (5.6%) 175 (28.3%) 440 (71.1%) <0.001 43 (5.4%) 280 (35.6%) 640 (81.1%) <0.001
Mean blood pressure, mmHg 93.7 ± 12.0 96.2 ± 11.2 98.8 ± 11.8 <0.001 89.3 ± 12.2 91.9 ± 12.9 95.4 ± 12.7 <0.001
Glucose, mg/dL 82.6 ± 9.7 85.3 ± 14.5 86.6 ± 11.9 <0.001 79.9 ± 7.3 80.8 ± 10.5 82.2 ± 11.5 <0.001
Total cholesterol, mg/dL 171.3 ± 27.7 178.7 ± 26.7 183.2 ± 26.2 <0.001 174.3 ± 27.4 179.7 ± 28.0 183.7 ± 27.9 <0.001
Triglyceride, mg/dL 111.0 [87.0;146.5] 142.0 [108.5; 194.0] 176.0 [128.0; 236.5] <0.001 99.0 [80.0; 131.0] 119.0 [91.0; 160.0] 128.0 [99.0; 177.0] <0.001
HDL cholesterol, mg/dL 47.7 ± 11.2 43.0 ± 9.1 41.3 ± 8.6 <0.001 48.7 ± 10.6 45.4 ± 9.9 45.0 ± 9.4 <0.001
LDL cholesterol, mg/dL 98.5 ± 25.6 103.9 ± 26.0 104.9 ± 24.8 <0.001 103.2 ± 23.5 107.2 ± 24.2 109.4 ± 24.7 <0.001
CRP, mg/dL 0.11 [0.04; 0.19] 0.14 [0.07; 0.24] 0.16 [0.08; 0.27] <0.001 0.09 [0.03; 0.17] 0.12 [0.05; 0.21] 0.15 [0.08; 0.27] <0.001
Current smokier, n (%) 325 (52.7%) 256 (41.6%) 232 (37.8%) <0.001 30 (3.9%) 15 (1.9%) 21 (2.7%) 0.070
Current drinker, n (%) 437 (70.8%) 458 (74.4%) 444 (72.5%) 0.382 249 (31.8%) 222 (28.6%) 206 (26.2%) 0.049
Physical activity, n (%) <0.001 0.007
<7.5 METs-h/week 34 (5.8%) 38 (6.4%) 29 (4.8%) 59 (7.8%) 71 (9.3%) 91 (12.0%)
7.5–30 METs-h/week 309 (53.0%) 394 (66.7%) 419 (69.7%) 497 (65.4%) 506 (66.3%) 510 (67.5%)
>30 METs-h/week 240 (41.2%) 159 (26.9%) 153 (25.5%) 204 (26.8%) 186 (24.4%) 155 (20.5%)
Daily caloric intake, kcal/day 2016.1 ± 656.5 2020.3 ± 603.3 1998.0 ± 704.9 0.632 1914.9 ± 726.6 1901.1 ± 693.3 1897.0 ± 715.8 0.623
Daily protein intake, g/day 68.3 ± 27.4 69.4 ± 25.3 68.4 ± 28.1 0.997 64.8 ± 29.6 65.4 ± 33.9 63.7 ± 29.1 0.512
Daily fat intake, g/day 35.5 ± 20.6 36.2 ± 18.3 34.8 ± 19.7 0.552 31.3 ± 19.6 30.9 ± 22.1 29.5 ± 20.5 0.093
Daily carbohydrate intake, g/day 350.3 ± 108.2 349.0 ± 101.5 347.4 ± 117.3 0.654 339.5 ± 125.3 336.1 ± 112.2 340.1 ± 124.2 0.927
Taking anti-dyslipidemic medication, n (%) 0 (0.0%) 3 (1.2%) 3 (1.1%) 0.304 0 (0.0%) 1 (0.2%) 3 (0.7%) 0.238
Hypertension, n (%) 169 (27.3%) 188 (30.4%) 270 (43.6%) < 0.001 135 (17.1%) 179 (22.7%) 270 (34.2%) <0.001
Diabetes mellitus, n (%) 17 (2.7%) 18 (2.9%) 14 (2.3%) 0.762 10 (1.3%) 16 (2.0%) 16 (2.0%) 0.416
Data are presented as mean ±standard deviations and median (interquartile range) or number (%). p-values were derived from Student’s t-test for continuous variables and the Chi-square test for categorical
variables. p < 0.05 was considered statistically significant. Abbreviations: KoGES, Korean Genome and Epidemiology Study; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
CRP, C-reactive protein; METs, metabolic equivalent of tasks. T, Tertile.
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3.2. Longitudinal Relationship between FMR and the Incident Non-Achievement of LDL
Cholesterol Targets
Figure 2 shows the linear relationship between FMR and the incident non-achievement
of LDL cholesterol targets using Cox proportional hazard spline curves. As the continuous
FMR values increased, the risk of incident non-achievement of LDL cholesterol targets
increased in both men and women.
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Table 2 presents the results of a Cox proportional hazard analysis for the incidence
of non-achievement of LDL cholesterol targets according to the sex-specific FMR tertiles.
The HRs and 95% CIs for the incidence of non-achievement of LDL cholesterol targets in
the T2 and T3 tertiles vs. the referent T1 tertile were 1.65 (1.39–1.97) and 2.08 (1.75–2.47)
in men and 1.49 (1.28–1.73) and 1.72 (1.49–2.00) in women, respectively. After adjusting
for age, obesity, current smoking, current drinking, physical activity, total caloric intake,
MBP, plasma glucose, serum CRP, baseline serum LDL cholesterol levels, and taking anti-
dyslipidemic medication at baseline, the adjusted HRs and 95% CI for the incidence of
non-achievement of LDL cholesterol targets for the T2 and T3 tertiles vs. the referent
T1 tertile were 1.56 (1.29–1.90) and 1.86 (1.47–2.31) in men and 1.40 (1.18–1.66) and 1.31
(1.06–1.62) in women, respectively.




HR 95% CI p HR 95% CI p
Men
Unadjusted 1 (reference) 1.65 1.39–1.97 <0.001 2.08 1.75–2.47 <0.001
Model 1 1 (reference) 1.67 1.39–2.02 <0.001 2.14 1.73–2.65 <0.001
Model 2 1 (reference) 1.64 1.36–1.98 <0.001 2.05 1.65–2.54 <0.001
Model 3 1 (reference) 1.56 1.29–1.90 <0.001 1.86 1.47–2.31 <0.001
Women
Unadjusted 1 (reference) 1.49 1.28–1.73 <0.001 1.72 1.49–2.00 <0.001
Model 1 1 (reference) 1.42 1.21–1.67 <0.001 1.43 1.17–1.75 <0.001
Model 2 1 (reference) 1.40 1.19–1.65 <0.001 1.42 1.16–1.74 <0.001
Model 3 1 (reference) 1.40 1.18–1.66 <0.001 1.31 1.06–1.62 0.011
Model 1: Adjusted for age, obesity, current smoker, current drinker, physical activity, and total caloric intake. Model 2: Adjusted for all
variables used in Model 1 plus mean blood pressure, plasma glucose, and serum CRP level. Model 3: Adjusted for all variables used in
Model 2 plus baseline serum LDL cholesterol level, and taking anti-dyslipidemic medication at baseline. Abbreviations: HR, hazard ratio;
CI, confidence interval; LDL, low-density lipoprotein; CRP, C-reactive protein; T, tertile.
3.3. Proportions of Non-Achievement of LDL Cholesterol Targets in the Sex-specific FMR Tertile
Groups during the Follow-up Period
Table 3 represents a comparison of the estimated proportions of non-achievement
of LDL cholesterol targets among the sex-specific FMR tertile groups during the follow-
up periods using GEE models. In both the overall and post hoc analyses, the estimated
proportion of people with the non-achievement of LDL cholesterol targets in the T3 tertile
remained significantly higher than that in the T1 tertile during all follow-up periods for
both men and women, except for the sixth follow-up period in women. The group-by-time
interactions were significant for both men and women.
Table 3. Generalized estimating equation models predicting the effects of time on the proportions of non-achievement of
















1st f/u 15.0 (1.5) 25.1 (1.8) 32.1 (1.9)
group: p < 0.001
time: p < 0.001
group-by-time:
p = 0.002
< 0.001 < 0.001 0.008
2nd f/u 8.3 (1.2) 13.5 (1.5) 15.7 (1.6) 0.007 < 0.001 0.330
3rd f/u 17.4 (1.7) 24.8 (2.0) 30.1 (2.1) < 0.001 < 0.001 0.062
4th f/u 20.0 (1.8) 27.9 (2.0) 34.8 (2.2) 0.005 < 0.001 0.020
5th f/u 12.1 (1.6) 18.3 (1.8) 24.0 (2.0) 0.010 < 0.001 0.035
6th f/u 14.9 (1.7) 23.6 (2.0) 24.3 (2.1) 0.001 < 0.001 0.811
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Abbreviations: LDL, low-density lipoprotein; SE, standard error; T, tertile.
3.4. Comparison of the Predictive Powers of FMR and BMI for the Non-Achievement of LDL
Cholesterol Targets
Figure 4 compares the predictive powers of FMR and BMI for the non-achievement
of LDL cholesterol targets. The AUCs for FMR and BMI were 0.625 and 0.601 in men and
0.652 and 0.619 in women, respectively. The predictive power of FMR was significantly
higher than that of BMI for both men and women (p = 0.002 in men; p < 0.001 in women).
When comparing predictive powers between obese and non-obese subjects, we found that
that the predictive powers of FMR were significantly higher than those of BMI for both
men and women (p = 0.004 in obese men; p = 0.002 in obese women; p < 0.001 in non-obese
men; p = 0.009 in non-obese women).




Figure 4. Comparison of the predictive powers of FMR and BMI for non-achievement of LDL cholesterol targets in (a) 
men, (b) women, (c) obese men, (d) obese women, (e) non-obese men, and (f) non-obese women. Abbreviations: FMR, fat-
to-muscle ratio; BMI, body mass index; LDL, low-density lipoprotein. Figure 4. Comparison of the predictive powers of FMR and BMI for non-achievement of LDL
cholesterol targets in (a) men, (b) women, (c) obese men, (d) obese women, (e) non-obese men,
and (f) non-obese women. Abbreviations: FMR, fat-to-muscle ratio; BMI, body mass index; LDL,
low-density lipoprotein.
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4. Discussion
We examined the longitudinal relationship between FMR and the incidence of non-
achievement of LDL cholesterol targets. Our results showed an increasing trend in the
incidence of non-achievement of LDL cholesterol targets with higher FMR based on Cox
proportional hazard spline curves. We also found that the estimated proportion of people
with incident non-achievement of LDL cholesterol targets was significantly higher in
the highest FMR tertile compared with the lowest tertile during almost all follow-up
periods in both men and women. These significant results remained even considering
the higher proportion of participants who took anti-dyslipidemic medications of T2 or
T3 vs. T1 during the period in both men and women. The number of participants taking
anti-dyslipidemic medications according to the tertiles of fat-to-muscle ratio are shown in
Table S1. In addition, the predictive power of FMR for the incidence of non-achievement of
LDL cholesterol targets was significantly higher than that of BMI among total, obese, and
non-obese subjects.
To the best of our knowledge, this study is the first longitudinal study to examine the
association between FMR and the incidence of non-achievement of LDL cholesterol targets.
Seo et al. revealed that high FMR was significantly associated with the prevalence of
metabolic syndrome and insulin resistance and determined sex-specific optimal FMR cutoff
values to predict metabolic syndrome in a Korean population [14]. Similarly, Chen et al.
showed significant associations between FMR and metabolic syndrome, diabetes mellitus,
and hypertension, suggesting the usefulness of FMR as a predictive index for cardio-
metabolic risks [27]. Our results are consistent with previous studies showing a strong
relationship between FMR and CVD risk [14,27] and are strengthened by data from a
longitudinal, prospective cohort study.
Several possible mechanisms support our results. Accumulated evidence has demon-
strated a relationship between increased fat mass and dyslipidemia. The most likely
contributing factor for adiposity-related dyslipidemia is uncontrolled fatty acid lipolysis,
leading to the increased delivery of FFA to the liver, upregulating triglyceride synthesis,
and exacerbating dyslipidemia [4,5]. In addition, excessive body fat increases the secretion
of pro-inflammatory adipokines, such as tumor necrosis factor-α and serum amyloid A,
by both adipocytes and adipose tissue-associated macrophages [28,29]. Conversely, the
secretion of anti-inflammatory adipokines may be decreased. This imbalance between
pro- and anti-inflammatory adipokines may lead to impaired insulin sensitivity in adipose
tissue, increasing the concentrations of FFA and promoting dyslipidemia [28,29]. Although
the direct mechanisms underlying the relationship between muscle mass and dyslipidemia
remain relatively unclear, several plausible explanations exist. Skeletal muscle is considered
an important insulin-responsive endocrine organ, and decreased muscle mass contributes
to impaired glycemic control and insulin resistance [30], which could contribute to the de-
velopment of atherogenic dyslipidemia [31]. The accumulation of intra- and inter-muscular
adipose tissue, accompanied by decreased muscle mass, can induce muscle inflammation
and negatively regulate myocyte metabolism, leading to insulin resistance [32,33].
Interestingly, we observed a small difference in sex in the association between FMR
and the non-achievement of LDL cholesterol targets. In the GEE models, the estimated
proportions of people with incident non-achievement of LDL cholesterol targets in the
T2 and T3 tertiles showed no significant differences from the proportions in the post
hoc analyses for both men and women. However, the estimated proportions of incident
non-achievement of LDL cholesterol targets in the T2 tertile at the fifth follow-up and
in the T3 tertile at the sixth follow-up were not significantly different from those in the
T1 tertile among women. Although the reasons for these differences remain unclear,
sexual dimorphism of body fat distribution [34] and changes in the body composition after
menopause due to sex hormones in women [35] might affect this result.
Our second aim was to compare the predictive powers between FMR and BMI for
the incidence of non-achievement of LDL cholesterol targets. Whether obesity or body
fat indicators other than BMI can present better predictive power for CVD risk than BMI
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remains controversial. Several studies have shown that waist circumference and body
fat percentage are more strongly associated with CVD risk factors than BMI [36,37]. For
example, Byambasukh et al. identified that body fat percentage measured by BIA was
independently associated with incident CVD events, and the predictive value of body
fat percentage was superior to both BMI and waist circumference in a prospective cohort
study [37]. Conversely, other studies have shown that BMI, which is a simple and inex-
pensive measure, remains a better predictor of CVD risk than other obesity indicators [38].
These inconsistent findings may be associated with differences in clinical characteristics
or inherent shortcomings of each measure, such as the BMI-associated misclassification
of individuals with high muscle mass as obese [39] and the underestimation of body fat
percentages measured by BIA [40]. In this study, we found that the predictive power of
FMR for the incidence of non-achievement of LDL cholesterol targets was higher than that
of BMI in both men and women. When analyzed by subgroups of obese and non-obese men
and women, FMR was a better predictor of dyslipidemia than BMI. Our findings suggest
the potential for using FMR as an obesity indicator to compensate for the shortcomings of
BMI, which does not adequately reflect body composition.
This study has several limitations. First, we did not consider the effects of changes
during the follow-up period, including any changes in fat and muscle mass that would
affect FMR levels or changes in other covariates. The consideration of changes in body
composition and other covariates during the follow-up period will be incorporated into
the next study. Second, fat mass and skeletal muscle mass were measured by BIA instead
of dual-energy X-ray absorptiometry, which is considered a more reliable method for body
composition assessment [41]. However, BIA is a popular, inexpensive, non-invasive, and
validated measurement. Third, we could not assess the contributions of fat distribution to
the association between FMR and the non-achievement of LDL cholesterol targets. FMR
was calculated using only total fat mass and total skeletal muscle mass. Evidence has
suggested the relative importance of visceral fat rather than subcutaneous fat to increased
CVD risk [42]. Fourth, some major CVD risk factors were not completely assessed due to
a lack of information regarding the incidence of carotid artery stenosis, peripheral artery
disease, and abdominal aortic aneurysm. Fifth, serum LDL cholesterol level was not
measured directly. Although we excluded participants whose serum triglyceride level
was ≥400 mg/dL, the Friedewald equation tends to underestimate participants’ LDL
cholesterol level in those with serum triglyceride level of 200–399 mg/dL [43]. In addition,
the number of participants taking anti-dyslipidemic medications was low during the
period. Prior guidelines on the management of dyslipidemia, which set the LDL cholesterol
level target < 100 mg/dL in coronary heart disease (CHD), and CHD risk equivalent
made doctors prescribe anti-dyslipidemic medications less often than now [44,45]. In
the baseline survey, participants may be relatively unaware of whether they were taking
anti-dyslipidemic medications. There is also lack of information about the type of anti-
dyslipidemic medications such as statin in KoGES data. Therefore, information bias should
be taken into account in this study. Finally, selection bias should be considered due to
the relatively high proportion of missing values, especially associated with the lack of
body composition data using BIA. Therefore, these results should be interpreted with
caution. Despite these weaknesses, our study has several strengths. To the best of our
knowledge, this study is the first to examine the association between FMR and incidence of
non-achievement of LDL cholesterol targets based on individual CVD risk levels, using a
large, prospective cohort study. Moreover, we compared the predictive power of FMR with
that of BMI to demonstrate the usefulness of FMR.
5. Conclusions
In conclusion, high FMR is significantly associated with an increased risk of non-
achievement of LDL cholesterol targets. Furthermore, FMR is a better predictor of the
non-achievement of LDL cholesterol targets than BMI. Therefore, we suggest that FMR,
which reflects the combined effects of fat and muscle mass, can serve as a novel indicator for
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the possibility of maintaining optimal LDL cholesterol levels according to individualized
CVD risk.
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